Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Ocugen, Inc. - Common Stock
(NQ:
OCGN
)
1.410
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 12, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Ocugen, Inc. - Common Stock
< Previous
1
2
...
15
16
17
18
19
20
21
22
23
...
35
36
Next >
Ocugen Stock Finally Sunk to Penny Status, But That Doesn’t Make It a Buy
↗
February 21, 2022
An interview with Dr. Anthony Fauci about the Covaxin vaccine makes you wonder why investors have any interest in OCGN stock.
Via
InvestorPlace
Americans’ Appetite for Vaccine Options Bodes Well for Ocugen
↗
February 21, 2022
OCGN stock is definitely out of favor on Wall Street, but fresh poll data and an imminent R&D hub acquisition should spur some optimism.
Via
InvestorPlace
Ocugen Stock Is a Fairy Tale in Need of a Happy Ending
↗
February 18, 2022
If you’re investing in OCGN stock, you have to wonder: how much upside can FDA approval really give this beleaguered name?
Via
InvestorPlace
Novavax Stock Is at Risk Despite Positive Poll Results
↗
February 16, 2022
A recent poll supports Novavax's Covid treatment in the United States, but the vote on today's NVAX stock price chart warns against buying.
Via
InvestorPlace
Who's Winning - The 'Shorters' Or The 'Squeezers'?
↗
February 14, 2022
A look at how well the 'squeezers' are doing relative to the
Via
Talk Markets
Two Reasons to Skip Ocugen Stock Despite Some Good News
↗
February 09, 2022
Ocugen was one of the most explosive stocks on the market, all thanks to its coronavirus vaccine, Covaxin. But don't rush to buy just yet.
Via
InvestorPlace
Ocugen To Buy Liminal's Dormant Vaccine Manufacturing Plant In Canada
↗
January 27, 2022
Ocugen Inc (NASDAQ: OCGN) has
Via
Benzinga
Can the Faithful Provide a Lifeline to Ocugen?
↗
January 14, 2022
While it’s an extremely speculative idea, OCGN stock may receive a lifeline from the faith-based community due to a recent tragedy.
Via
InvestorPlace
OCGN Stock Alert: Why Is Ocugen Soaring 10% Today?
↗
January 12, 2022
Shares of OCGN stock are in the green after Covaxin demonstrated strong protection against the omicron and delta variants.
Via
InvestorPlace
With No Vaccine Approval, Ocugen Is the Definition of Dead Money
↗
February 09, 2022
Holding out hope for a Covid vaccine approval that might never come, OCGN stock is too risky while the company has no revenue.
Via
InvestorPlace
3 Biotech Stocks That Could Boom or Bust in Q1
↗
February 01, 2022
The biotech industry is exploding. Biotech stocks provide lots of opportunities for investors who are taking a risk on the medicine's future.
Via
InvestorPlace
Despite Big Disappointment, There’s Still Potential With Ocugen Stock
↗
January 25, 2022
As this biotech's stock continues to slide lower in price, risk-tolerant investors may find an opportunity with beaten down OCGN stock.
Via
InvestorPlace
20 Stocks Moving in Tuesday's Pre-Market Session
↗
January 25, 2022
Gainers Aptorum Group Limited (NASDAQ: APM) shares rose 94.4% to $3.15 in pre-market trading after gaining around 10% on Monday. The FDA recently granted Orphan Drug Designation...
Via
Benzinga
Novavax Appears to be Running Out of Options
↗
January 25, 2022
With time appearing to run out and fewer people willing to get vaccinated, NVAX stock seems to be an abandon-ship investment at this point.
Via
InvestorPlace
OCGN Stock Alert: Why Is Ocugen Gaining Today?
↗
January 10, 2022
Ocugen's stock is up more than 5% after the latest clinical trial results showed its Covid-19 vaccine booster shot had positive results.
Via
InvestorPlace
7 Penny Stock Bubbles That Are Bound to Burst
↗
January 21, 2022
Watch out with these seven penny stocks, a mix of plays that are still flying high, and a few that have already seen their bubble deflate.
Via
InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
↗
January 20, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our...
Via
Benzinga
7 Robinhood Stocks You Can Still Buy for Under $5
↗
January 19, 2022
Although 2021 has been a blistering year for equities, there are still some speculative Robinhood stocks to buy under $5.
Via
InvestorPlace
Looking Into Ocugen Inc's Recent Short Interest
↗
January 12, 2022
Ocugen Inc's (NASDAQ:OCGN) short percent of float has risen 9.83% since last its last report. The company recently reported that it has 54.30 million shares sold short, which is...
Via
Benzinga
Ocugen-Bharat Biotech Partnered COVID-19 Booster Covaxin Neutralizes Omicron, Delta Variants
↗
January 12, 2022
Ocugen Inc (NASDAQ: OCGN) and its partner, Bharat Biotech, announced results from a COVID-19 vaccine booster study conducted at Emory University. The data demonstrated sera...
Via
Benzinga
The Daily Biotech Pulse: Biogen Slumps As CMS Announces Restrictive Coverage For Aduhelm, Aclaris CMO Departs, Immuron Spikes On US Military Award
↗
January 12, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Biogen Shares Slip On Restricted Coverage For Its Alzheimer's Drug Biogen...
Via
Benzinga
CPNG Stock: Why Are Coupang Shares Getting Clobbered Today?
↗
January 10, 2022
Coupang (CPNG) stock is falling on Monday despite a lack of news and we're diving into possible reasons why that's happening today.
Via
InvestorPlace
LULU Stock: 6 Reasons Why Lululemon Investors Are Feeling Short of Breath Today
↗
January 10, 2022
Lululemon Athletica (LULU) stock is taking a beating on Monday after releasing updated expectations for its Q4 2021 earnings report.
Via
InvestorPlace
EV Stocks: Why Are TSLA, RIVN, XPEV, RIDE, NKLA and LCID Riding Lower Today?
↗
January 10, 2022
Electric vehicle (EV) stocks are on the move Monday as investors continue to react to warnings about rising interest rates.
Via
InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
↗
January 10, 2022
Welcome back, trader! We're starting off the week with a breakdown of the biggest pre-market stock movers for Monday morning!
Via
InvestorPlace
20 Stocks Moving in Monday's Pre-Market Session
↗
January 10, 2022
Gainers Bone Biologics Corporation (NASDAQ: BBLG) rose 32.1% to $4.53 in pre-market trading. Pluristem Therapeutics Inc. (NASDAQ: PSTI) rose 28.5% to $1.89 in pre-...
Via
Benzinga
Ocugen Reveals Data From Bharat Biotech Partnered Covaxin Booster Dose
↗
January 10, 2022
Ocugen Inc (NASDAQ: OCGN) announced that a booster shot of the COVID-19 vaccine candidate generated over a 10-fold increase in antibody levels across a range of...
Via
Benzinga
The Top 3 Robinhood Stocks of 2021
↗
January 07, 2022
The Robinhood trading platform is controversial, but it has drawn investors to many stocks that have posted big gains in the last year.
Via
InvestorPlace
Top 10 Most Searched Tickers On Benzinga Pro In 2021: Tesla, Apple, AMC, GameStop And More
↗
January 02, 2022
Many of Benzinga’s most read stories in 2021 centered on the world of cryptocurrency, with Dogecoin (CRYPTO: DOGE) receiving huge interest from investors and readers. That...
Via
Benzinga
Ocugen Stock Is Essentially Back to Being an Eye Disease Play
↗
December 30, 2021
OCGN stock has a tough path to entry in the North American market and time isn't on its side. It looks as if the coronavirus ship has sailed.
Via
InvestorPlace
< Previous
1
2
...
15
16
17
18
19
20
21
22
23
...
35
36
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.